TABLE 2.

Comparison of sensitivities and specificities for the VlsE and C6 assays for the detection of B. burgdorferi antibodies

Patient groupnVlsE assayC6 assayWB
No. with result of:Sen.c (%)Spe.d (%)No. with result of:Sen. (%)Spe. (%)No. with result of:Sen. (%)Spe. (%)
+++
CDC panel I (culture confirmed)
    Early localized diseasea1913668.411857.991047.4
    Early disseminated diseaseb41311075.633880.5311075.6
CDC panel II
    Healthy505100.005100.005100.0
    Early disease (<2 mo)26161061.520676.917965.4
    Late disease (>2 mo)11110100.0110100.0110100.0
Non-LD
    CMV20020100.0020100.0
    EBV20020100.0020100.0
    HAMA positive102880.01990.0
    Healthy, nonendemice300229899.3729397.7
    Healthy, endemicf300129999.7229899.3
    Helicobacter pylori2011995.0020100.0
    HIV20020100.0020100.0
    LYMErix vaccine11011100.0011100.0
    Multiple sclerosis808100.008100.0
    Rheumatoid arthritis2021890.021890.0
    RF positive10010100.0010100.0
    Syphilis patients18018100.0018100.0
    Systemic lupus erythematosus20020100.0020100.0
    Tick-borne relapsing fever107330.04660.0
    Various autoimmune diseases (e.g., systemic sclerosis, Sjögren's syndrome)2011995.011995.0
    Total8071679198.01779097.9
  • a Nine collected at baseline presentation, 10 collected 1 to 3 weeks after presentation and treatment.

  • b Twelve collected at baseline presentation, 29 collected 1 to 3 weeks after presentation and treatment.

  • c Sen., sensitivity.

  • d Spe., specificity.

  • e Subjects from an area where LD is not endemic.

  • f Subjects from an area where LD is endemic.